EyeBiotech
A biopharmaceutical company that develops therapies for the treatment of retinal diseases.
EyeBiotech has raised €118M across 2 funding rounds from 7 investors, most recently a Series A round in Nov 2023. Based in London, UK; active in Healthtech. Data as of 28 Oct 2026.
London, UKeyebiotech.com ↗
Total raised
€118M
€117,920,829
Funding rounds
2
Investors
7
distinct backers
Active since
2022-02
latest 2023-11
Funding by year
EUR raised per yearEyeBiotech — funding by year — interactive chart.
Data table
| EyeBiotech — funding by year | |
|---|---|
| 2022 | €57M |
| 2023 | €61M |
Signals
High confidenceRaise-next likelihood14
base rate 44% for Series A
- ▼ Past typical raise window
- ▼ Low backer re-investment
Exit likelihood11
base rate 11% (2+ rounds)
- ▲ €100M+ raised
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-11-14 | Series A | €61M | Bain Capital Life Sciences,Jeito Capital,MRL Ventures Fund,Omega Funds,Samsara Biocapital,SV Health Investors+1 more | View deal → |
| 2022-02-22 | Series A | €57M | Jeito Capital,MRL Ventures Fund,Samsara Biocapital,SV Health Investors | View deal → |
Investors
7Related news
- EyeBiotech Raises $65M in Series A Fundingfinsmes.com · 2022-02
- finsmes.com
Similar companies
same sector or countryGlobal coverage: FundingData